Sanofi Arixtra longer treatment duration
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sanofi-Synthelabo/Organon's Arixtra (fondaparinux) adds an extended course of treatment for prophylaxis of deep vein thrombosis. FDA cleared the anti-thrombotic agent June 17 for up to 24 days of DVT prophylaxis in patients undergoing hip fracture surgery. Previously, Arixtra was recommended for a five- to nine-day administration perio
You may also be interested in...
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.